Item 8.01. Other Events.



On March 2, 2021, BeiGene, Ltd. (the "Company") announced that BRUKINSA®
(zanubrutinib) has been approved by Health Canada for the treatment of adult
patients with Waldenström's Macroglobulinemia ("WM"). On September 9, 2020, the
Company previously announced that its New Drug Submission ("NDS") for BRUKINSA®
(zanubrutinib) for the treatment of patients with WM had been accepted by Health
Canada and granted priority review status. The full text of this press release
is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.           Description

       99.1              Press Release titled "Health Canada Approves

BRUKINSA® (Zanubrutinib) for the


                         Treatment of Waldenström's Macroglobulinemia"

issued on March 2, 2021.


       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------



                                 Exhibit Index

   Exhibit No.           Description

       99.1                Press Release titled "Health Canada Approves BRUKINSA    ®     (Zanubrutinib)
                         for the Treatment of Waldenström's Macroglobulinemia"     issued on March 2,
                         2021.

       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses